L P Hoehle1,2, K M Phillips1,2, D S Caradonna2,3, S T Gray1,2, A R Sedaghat4,5,6,7. 1. Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, 243 Charles Street, Boston, MA, 02114, USA. 2. Department of Otolaryngology, Harvard Medical School, Boston, MA, USA. 3. Division of Otolaryngology, Beth Israel Deaconess Medical Center, Boston, MA, USA. 4. Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, 243 Charles Street, Boston, MA, 02114, USA. ahmad_sedaghat@meei.harvard.edu. 5. Department of Otolaryngology, Harvard Medical School, Boston, MA, USA. ahmad_sedaghat@meei.harvard.edu. 6. Division of Otolaryngology, Beth Israel Deaconess Medical Center, Boston, MA, USA. ahmad_sedaghat@meei.harvard.edu. 7. Department of Otolaryngology and Communications Enhancement, Boston Children's Hospital, Boston, MA, USA. ahmad_sedaghat@meei.harvard.edu.
Abstract
BACKGROUND: Chronic rhinosinusitis (CRS) is highly prevalent, significantly decreases quality of life and leads to tremendous health care costs every year. No recent study has characterised the prevalence of potentially CRS-modifying patient characteristics and simultaneously shown their impact on CRS severity. AIMS: We sought to determine the prevalence of potential clinical and demographic CRS-modifying characteristics and their associations with CRS symptom severity in a large contemporary cohort of CRS patients. METHODS: Retrospective review of CRS patients who visited our rhinology clinics between February 2016 and February 2017 was conducted. CRS symptom severity was measured using the 22-item Sinonasal Outcomes Test (SNOT-22) questionnaire, which all patients received. Association was sought between SNOT-22 score (as dependent variable) and patients' clinical and demographic characteristics using linear regression. RESULTS: Of the 572 included patients, the mean age was 51.1 years (SD = 15.8) and the mean SNOT-22 score was 34.3 (SD = 22.6). Prevalence of granulomatous diseases, immunodeficiency and cystic fibrosis were each approximately 5%. Prevalence of aeroallergen hypersensitivity was 42.3% and prevalence of asthma was 27.8%. More severe CRS symptomatology was associated with smoking tobacco (adjusted β = 5.47, p = 0.034) and comorbid asthma (adjusted β = 12.02, p < 0.001), whilst less severe symptomatology was associated with older age (adjusted β = -0.23, p = 0.002) and diagnosis of cystic fibrosis (adjusted β = -11.87, p = 0.009). CONCLUSIONS: In a contemporary cohort of CRS patients, prevalence of disease-modifying comorbidities ranged from approximately 5 to over 40%. Smoking tobacco and asthma were associated with more severe CRS symptomatology, whilst older age and diagnosis of cystic fibrosis were associated with less severe CRS symptomatology.
BACKGROUND:Chronic rhinosinusitis (CRS) is highly prevalent, significantly decreases quality of life and leads to tremendous health care costs every year. No recent study has characterised the prevalence of potentially CRS-modifying patient characteristics and simultaneously shown their impact on CRS severity. AIMS: We sought to determine the prevalence of potential clinical and demographic CRS-modifying characteristics and their associations with CRS symptom severity in a large contemporary cohort of CRSpatients. METHODS: Retrospective review of CRSpatients who visited our rhinology clinics between February 2016 and February 2017 was conducted. CRS symptom severity was measured using the 22-item Sinonasal Outcomes Test (SNOT-22) questionnaire, which all patients received. Association was sought between SNOT-22 score (as dependent variable) and patients' clinical and demographic characteristics using linear regression. RESULTS: Of the 572 included patients, the mean age was 51.1 years (SD = 15.8) and the mean SNOT-22 score was 34.3 (SD = 22.6). Prevalence of granulomatous diseases, immunodeficiency and cystic fibrosis were each approximately 5%. Prevalence of aeroallergen hypersensitivity was 42.3% and prevalence of asthma was 27.8%. More severe CRS symptomatology was associated with smoking tobacco (adjusted β = 5.47, p = 0.034) and comorbid asthma (adjusted β = 12.02, p < 0.001), whilst less severe symptomatology was associated with older age (adjusted β = -0.23, p = 0.002) and diagnosis of cystic fibrosis (adjusted β = -11.87, p = 0.009). CONCLUSIONS: In a contemporary cohort of CRSpatients, prevalence of disease-modifying comorbidities ranged from approximately 5 to over 40%. Smoking tobacco and asthma were associated with more severe CRS symptomatology, whilst older age and diagnosis of cystic fibrosis were associated with less severe CRS symptomatology.
Authors: D Jarvis; R Newson; J Lotvall; D Hastan; P Tomassen; T Keil; M Gjomarkaj; B Forsberg; M Gunnbjornsdottir; J Minov; G Brozek; S E Dahlen; E Toskala; M L Kowalski; H Olze; P Howarth; U Krämer; J Baelum; C Loureiro; L Kasper; P J Bousquet; J Bousquet; C Bachert; W Fokkens; P Burney Journal: Allergy Date: 2011-11-04 Impact factor: 13.146
Authors: Katie M Phillips; Lloyd P Hoehle; Regan W Bergmark; David S Caradonna; Stacey T Gray; Ahmad R Sedaghat Journal: J Allergy Clin Immunol Pract Date: 2016-11-07
Authors: Marlene M Speth; Katie M Phillips; Lloyd P Hoehle; David S Caradonna; Stacey T Gray; Ahmad R Sedaghat Journal: Eur Arch Otorhinolaryngol Date: 2019-07-19 Impact factor: 2.503
Authors: Rehab Talat; Katie M Phillips; David S Caradonna; Stacey T Gray; Ahmad R Sedaghat Journal: Eur Arch Otorhinolaryngol Date: 2019-07-15 Impact factor: 2.503
Authors: Claire Gleadhill; Marlene M Speth; Isabelle Gengler; Katie M Phillips; Lloyd P Hoehle; David S Caradonna; Stacey T Gray; Ahmad R Sedaghat Journal: Eur Arch Otorhinolaryngol Date: 2020-08-04 Impact factor: 2.503
Authors: David T Liu; Katie M Phillips; Firas A Houssein; Marlene M Speth; Gerold Besser; Christian A Mueller; Ahmad R Sedaghat Journal: Laryngoscope Date: 2022-03-30 Impact factor: 2.970